| Original language | English (US) |
|---|---|
| Pages (from-to) | 652-654 |
| Number of pages | 3 |
| Journal | Circulation |
| Volume | 146 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 23 2022 |
Keywords
- cardiovascular diseases
- diabetes mellitus, type 2
- metformin
- sodium-glucose transporter 2 inhibitors
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Circulation, Vol. 146, No. 8, 23.08.2022, p. 652-654.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use
T2 - Post Hoc Analyses of the VERTIS CV Trial
AU - Cosentino, Francesco
AU - Cannon, Christopher P.
AU - Frederich, Robert
AU - Cherney, David Z.I.
AU - Dagogo-Jack, Samuel
AU - Pratley, Richard E.
AU - Mancuso, James P.
AU - Maldonado, Mario
AU - Cater, Nilo B.
AU - Wang, Shuai
AU - McGuire, Darren K.
N1 - Funding Information: This study was sponsored by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, in collaboration with Pfizer Inc., New York, NY. Funding Information: Dr Cosentino has received research grants from the Swedish Research Council, Swedish Heart & Lung Foundation, and King Gustav V and Queen Victoria Foundation; and has received consulting fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Mundipharma, Novo Nordisk, and Pfizer Inc. Dr Cannon has received research grants from Amgen, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Merck, Novo Nordisk, Pfizer, and fees from Aegerion/Amryt, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Lexicon, Merck, Pfizer, Rhoshan, and Sanofi; and serves on Data and Safety Monitoring Boards for the Veteran’s Administration, Applied Therapeutics, and Novo Nordisk. Dr Cherney has received consulting fees and speaking honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Merck & Co., Inc., Mitsubishi-Tanabe, Novo Nordisk, Prometic, and Sanofi; and has received operating funds from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck & Co., Inc., Novo Nordisk, and Sanofi. Dr Dagogo-Jack has led clinical trials for AstraZeneca, Boehringer Ingelheim, and Novo Nordisk Inc.; has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck & Co., Inc., and Sanofi; and has equity interests in Jana Care Inc. and Aerami Therapeutics. Dr Pratley has received grants (directed to his institution) from Hanmi Pharmaceutical Co., Ltd, Janssen, Metavention, Novo Nordisk, Poxel SA, and Sanofi; has received consulting fees (directed to his institution) from AstraZeneca, Corcept Therapeutics Incorporated, Glytec LLC, Hanmi Pharmaceutical Co., Ltd, Janssen, Merck & Co., Inc., Mundipharma, Novo Nordisk, Pfizer Inc., Sanofi, Scohia Pharma Inc., and Sun Pharmaceutical Industries; and has received support for attending meetings/travel (directed to his institution or to the travel provider) from AstraZeneca, Glytec LLC, Merck & Co., Inc., Mundipharma, Novo Nordisk, and Pfizer Inc. Dr McGuire has received consulting fees from Afimmune, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Lexicon, Lilly USA, Merck Sharp & Dohme, Metavant, Novo Nordisk, Pfizer Inc., and Sanofi US; has received honoraria from Boehringer Ingelheim; has received payment for expert testimony from Kirkland & Ellis on behalf of Boehringer Ingelheim; and has participated on data safety monitoring boards/advisory boards for CSL Behring, AbbVie, Eidos, Otsuka, Arena, and Akebia. Dr Maldonado is an employee of MSD Limited, London, UK, and owns stock in Merck & Co., Inc., Rahway, NJ. Drs Frederich, Mancuso, and Cater are employees and shareholders of Pfizer Inc. Dr Wang was an employee and shareholder of Pfizer Inc. at the time the study was conducted.
PY - 2022/8/23
Y1 - 2022/8/23
KW - cardiovascular diseases
KW - diabetes mellitus, type 2
KW - metformin
KW - sodium-glucose transporter 2 inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85136174947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136174947&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.121.058294
DO - 10.1161/CIRCULATIONAHA.121.058294
M3 - Letter
C2 - 35994565
AN - SCOPUS:85136174947
SN - 0009-7322
VL - 146
SP - 652
EP - 654
JO - Circulation
JF - Circulation
IS - 8
ER -